2018 AANS Annual Scientific Meeting-760. Outcomes of Adoptive Cell Transfer with Tumor-Infiltrating Lymphocytes for Metastatic Melanoma Patients with and without Brain Metastases

760. Outcomes of Adoptive Cell Transfer with Tumor-Infiltrating Lymphocytes for Metastatic Melanoma Patients with and without Brain Metastases

Back to course

Video Transcription

Video Summary

In this video, Gautam Mehta discusses the clinical outcomes of adoptive self-transfer with TILs (tumor-infiltrating lymphocytes) for patients with melanoma brain metastases. Mehta explains that melanoma brain metastases have poor survival rates, and traditional immunotherapy options have limited effectiveness. However, adoptive self-transfer has shown promising results with a response rate of up to 40% in brain metastases. Mehta then presents a study that compares the outcomes of patients with untreated brain metastases to those without brain metastases or with treated brain metastases. The study found that patients with untreated brain metastases had worse progression-free survival and overall survival. Mehta concludes that patients with untreated brain metastases should undergo treatment targeting those sites before receiving adoptive cell transfer immunotherapy.

Asset Caption

Gautam Unmeel Mehta, MD

Keywords

Gautam Mehta

clinical outcomes

adoptive self-transfer

TILs

melanoma brain metastases